{"id":439746,"date":"2021-02-19T07:03:17","date_gmt":"2021-02-19T12:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439746"},"modified":"2021-02-19T07:03:17","modified_gmt":"2021-02-19T12:03:17","slug":"gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/","title":{"rendered":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference"},"content":{"rendered":"

<\/p>\n

Gemini Therapeutics to Participate in the SVB Leerink 10th<\/sup> Annual Global Healthcare Conference<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th<\/sup> Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET.\n<\/p>\n

\nA live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.\n<\/p>\n

About Gemini Therapeutics<\/b><\/p>\n

\nGemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini\u2019s lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.\n<\/p>\n

\nFor more information, visit www.geminitherapeutics.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210219005014\/en\/<\/a><\/span><\/p>\n

Gemini Investor Contact:
\n<\/b>
Argot Partners
\n
Sherri Spear
\n
212-600-1902
\n
gemini@argotpartners.com<\/a><\/p>\n

Gemini Media Contact:
\n<\/b>
Argot Partners
\n
Joshua Mansbach
\n
212-600-1902
\n
gemini@argotpartners.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Other Health Biotechnology General Health Pharmaceutical Health Optical Science Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage … <\/p>\n

Continue reading “Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage … Continue reading "Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T12:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference\",\"datePublished\":\"2021-02-19T12:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/\"},\"wordCount\":280,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/\",\"name\":\"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-02-19T12:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk","og_description":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage … Continue reading \"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T12:03:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference","datePublished":"2021-02-19T12:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/"},"wordCount":280,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/","name":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-02-19T12:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210219005014r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}